The KIF16B Knockout NCI-H1975 Polyclonal Cells represent a precisely engineered CRISPR/Cas9-mediated polyclonal knockout cell population designed to disrupt the KIF16B gene in the NCI-H1975 human non-small cell lung adenocarcinoma cell line. This product provides a heterogeneous pool of edited cells, reflecting a range of loss-of-function mutations at the target locus, and is suitable for functional studies requiring a broad representation of genetic modifications. The polyclonal format circumvents clonal selection bottlenecks, enabling more physiologically relevant population-level analyses of KIF16B-dependent phenotypes. This knockout model serves as a fundamental tool for dissecting the cellular roles of KIF16B in endosomal trafficking and cancer biology.
The parental NCI-H1975 cell line was originally derived from the lung adenocarcinoma of a 73-year-old female patient and is characterized by the presence of the oncogenic EGFR L858R mutation. This mutation confers constitutive activation of the epidermal growth factor receptor (EGFR), leading to persistent downstream signaling that drives tumor growth and survival. As a widely used model for EGFR-mutant lung adenocarcinoma, NCI-H1975 cells recapitulate key features of the disease, including dependence on mutant EGFR signaling and sensitivity to EGFR tyrosine kinase inhibitors. The genetic background of this cell line provides a clinically relevant context for studying the contributions of accessory pathways, such as those involving KIF16B, to cancer progression.
KIF16B encodes a kinesin-3 family motor protein that functions as a critical regulator of early endosome dynamics. It is recruited to endosomal membranes through direct interaction with Rab5 and phosphatidylinositol 3-phosphate (PI3P), coupling these vesicles to microtubule-based transport. This motile activity governs the spatial distribution of early endosomes and influences the trafficking itinerary of internalized receptors, most notably EGFR. Within the EGFR signaling cascade, KIF16B operates downstream of receptor activation and Rab5, yet upstream of endosomal maturation events marked by EEA1 and Rab7. By modulating the perinuclear localization and fate of endosomes, KIF16B controls the balance between receptor recycling and degradation, thereby fine-tuning signaling output. Additionally, KIF16B-mediated endosome transport has been implicated in cell migration, likely through its effects on integrin and growth factor receptor recycling at the leading edge. Thus, KIF16B integrates signals from EGF and EGFR with the endosomal sorting machinery, acting as a node that connects membrane trafficking to cell motility.
In NCI-H1975 cells, oncogenic EGFR signaling intersects with endosomal compartments that are orchestrated by KIF16B. Disruption of KIF16B function in this model may perturb EGFR degradation kinetics, influence downstream mitogenic and survival pathways, and alter migratory behavior. Given the high prevalence of EGFR mutations in non-small cell lung cancer, understanding how endocytic trafficking modulates mutant EGFR biology is of considerable therapeutic interest. The KIF16B knockout NCI-H1975 polyclonal cells thus allow researchers to probe the role of endosome positioning in the pathogenesis of lung adenocarcinoma, with potential implications for addressing metastatic dissemination and drug resistance.
These polyclonal KIF16B knockout cells are amenable to a wide range of experimental approaches. Immunofluorescence microscopy can be used to visualize the subcellular distribution of early endosome markers (such as EEA1) and assess their microtubule-dependent localization in the absence of KIF16B. Functional assays, including transwell migration and Matrigel invasion, can quantify the impact of KIF16B loss on cell motility. EGFR degradation assays, employing cycloheximide chase or surface biotinylation followed by western blotting, enable kinetic analysis of receptor downregulation. Co-immunoprecipitation experiments with Rab5 remain feasible in the polyclonal background to evaluate remaining interacting partners. Overall, this product provides a robust platform for studying the intersection of endosomal trafficking, receptor signaling, and cell migration in an EGFR-mutant lung adenocarcinoma model. For additional information or technical support, please reach out to Ascent Research.
